Translating ENIGMA schizophrenia findings using the regional vulnerability index: Association with cognition, symptoms, and disease trajectory
暂无分享,去创建一个
J. Turner | T. V. van Erp | N. Jahanshad | P. Thompson | P. Kochunov | F. Fan | Xiaoming Du | L. Hong | B. Adhikari | Meghann C Ryan | Yunlong Tan | Mark D. Kvarta | H A Bruce | Shuping Tan | Stephanie M. Hare | Shuo Chen | Yi-min Cui | E. Goldwaser | K. Hatch | Jinghui Tong | Junchao Huang | Baopeng Cao | J. Tong | P. Thompson | P. Thompson
[1] Emily L. Dennis,et al. ENIGMA‐DTI: Translating reproducible white matter deficits into personalized vulnerability metrics in cross‐diagnostic psychiatric research , 2020, Human brain mapping.
[2] Yogesh Rathi,et al. White matter abnormalities across the lifespan of schizophrenia: a harmonized multi-site diffusion MRI study , 2019, Molecular Psychiatry.
[3] N. Jahanshad,et al. White Matter in Schizophrenia Treatment Resistance. , 2019, The American journal of psychiatry.
[4] P. Thompson,et al. Toward High Reproducibility and Accountable Heterogeneity in Schizophrenia Research. , 2019, JAMA psychiatry.
[5] Adrian Preda,et al. Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium , 2018, Biological Psychiatry.
[6] Dan J Stein,et al. Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group , 2017, Molecular Psychiatry.
[7] I. Melle,et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium , 2016, Molecular Psychiatry.
[8] S. Leucht,et al. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. , 2016, JAMA psychiatry.
[9] I. Melle,et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium , 2015, Molecular Psychiatry.
[10] T. Schulze,et al. Kraepelin revisited: schizophrenia from degeneration to failed regeneration , 2015, Molecular Psychiatry.
[11] P. Kochunov,et al. Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage. , 2014, Schizophrenia bulletin.
[12] P. Fitzgerald,et al. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age , 2014, Molecular Psychiatry.
[13] Paul M. Thompson,et al. Multi-site genetic analysis of diffusion images and voxelwise heritability analysis: A pilot project of the ENIGMA–DTI working group , 2013, NeuroImage.
[14] S K Holland,et al. DTI Values in Key White Matter Tracts from Infancy through Adolescence , 2013, American Journal of Neuroradiology.
[15] J N Giedd,et al. Neurodevelopmental model of schizophrenia: update 2012 , 2012, Molecular Psychiatry.
[16] D. Glahn,et al. Fractional anisotropy of water diffusion in cerebral white matter across the lifespan , 2012, Neurobiology of Aging.
[17] T. McGlashan. Eugen Bleuler: centennial anniversary of his 1911 publication of Dementia Praecox or the group of schizophrenias. , 2011, Schizophrenia bulletin.
[18] P. Fox,et al. Fractional anisotropy of cerebral white matter and thickness of cortical gray matter across the lifespan , 2011, NeuroImage.
[19] Paul M. Thompson,et al. Genetic Analysis of Cortical Thickness and Fractional Anisotropy of Water Diffusion in the Brain , 2011, Front. Neurosci..
[20] Gert Cauwenberghs,et al. Neuromorphic Silicon Neuron Circuits , 2011, Front. Neurosci.
[21] D. Jeste,et al. Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia. , 2011, Schizophrenia bulletin.
[22] Uniwersytet Jagielloński,et al. The Concept , 2010, The Knights Templar.
[23] A. David,et al. Processing speed deficits in schizophrenia: reexamining the evidence. , 2010, The American journal of psychiatry.
[24] Kelvin O. Lim,et al. Hybrid ICA-Seed-Based Methods for fMRI Functional Connectivity Assessment: A Feasibility Study , 2010, Int. J. Biomed. Imaging.
[25] T. Salthouse. When does age-related cognitive decline begin? , 2009, Neurobiology of Aging.
[26] Shu-ping Tan,et al. Clinical reliability and validity of the Chinese version of Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery , 2009 .
[27] Michael F. Green,et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. , 2008, The American journal of psychiatry.
[28] Michael F. Green,et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. , 2008, The American journal of psychiatry.
[29] J. Gold,et al. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. , 2007, Archives of general psychiatry.
[30] A. Addington,et al. The neurodevelopmental model of schizophrenia: update 2005 , 2005, Molecular Psychiatry.
[31] Margaret P. Poe,et al. Defining a cognitive function decrement in schizophrenia , 2005, Biological Psychiatry.
[32] Philip D. Harvey,et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery , 2004, Schizophrenia Research.
[33] Thomas F. Nugent,et al. Dynamic mapping of human cortical development during childhood through early adulthood. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[34] Suzanne E. Welcome,et al. Mapping cortical change across the human life span , 2003, Nature Neuroscience.
[35] D. Javitt,et al. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. , 2002, The American journal of psychiatry.
[36] Larry J Seidman,et al. Neuropsychologic functioning among the nonpsychotic relatives of schizophrenic patients: the effect of genetic loading , 2000, Biological Psychiatry.
[37] Adityanjee,et al. Dementia praecox to schizophrenia: The first 100 years , 1999, Psychiatry and clinical neurosciences.
[38] Daniel R. Weinberger,et al. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground , 1995, Schizophrenia Research.
[39] R. Murray,et al. A neurodevelopmental approach to the classification of schizophrenia. , 1992, Schizophrenia bulletin.
[40] G Honigfeld,et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.
[41] E. Bleuler. [Dementia praecox or the group of schizophrenias]. , 1968, Vertex.
[42] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[43] D. Charney,et al. Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative. , 2004, The American journal of psychiatry.
[44] Alexander L. Miller,et al. Practice guideline for the treatment of patients with schizophrenia, second edition. , 2004, The American journal of psychiatry.
[45] John H Krystal,et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. , 2003, Archives of general psychiatry.
[46] David A Lewis,et al. Schizophrenia as a disorder of neurodevelopment. , 2002, Annual review of neuroscience.
[47] J. Knoll,et al. Heterogeneity of the psychoses: is there a neurodegenerative psychosis? , 1998, Schizophrenia bulletin.
[48] R. McCarley,et al. Progressive changes in schizophrenia: do they exist and what do they mean? , 1998, Restorative neurology and neuroscience.
[49] Julie Kreyenbuhl,et al. Practice guideline for the treatment of patients with schizophrenia , 1997 .
[50] I. Feinberg,et al. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? , 1982, Journal of psychiatric research.
[51] Christian Beaulieu. Published online in Wiley InterScience (www.interscience.wiley.com). DOI:10.1002/nbm.782 Review Article , 2022 .